Bridge crossed by HeartWare
Tuesday, 23 September, 2008
The US FDA has approved the left ventricular assist system [LVAS] developed by HeartWare [ASX: HTW] for an Investigational Device Exemption (IDE).
The company is now clear to conduct clinical trials of the device, which are to be held at the Washington Hospital Centre, with one patient already enrolled.
The trial is a bridge-to-transplant trial in patients with end-stage heart failure.
HeartWare is in the process of finalising contractual arrangements at a number of additional centres. Seven centres so far have been trained in the use of the product.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
